Psilocybin as a Potential Therapy for Managing Depression and Anxiety in Cancer Patients
DOI:
https://doi.org/10.31004/joecy.v6i1.8905Keywords:
depression, cancer, anxiety, psilocybinAbstract
Background: Cancer patients often experience significant emotional burdens due to the diagnosis, treatment process, and uncertainty regarding their prognosis. Psilocybin, a psychedelic compound found in certain mushroom species, has gained increasing attention in mental health research for its potential therapeutic effects in treating depression and anxiety.
Methods: This systematic review analyzed literature regarding the effectiveness of psilocybin in treating anxiety and depression among cancer patients, following the PRISMA guidelines. Four studies were included, and data extraction was performed by three independent reviewers. The quality of the studies was assessed using the Risk of Bias 2 (RoB-2) tool.
Results: Psilocybin shows potential as an effective adjunct therapy to reduce depression and anxiety levels in cancer patients when administered in a controlled and supervised clinical setting. Several studies reported significant reductions in depressive and anxiety symptoms after psilocybin therapy. Patients described the experience as profound and transformative, helping them confront fears of death, alleviate cancer-related anxiety, and improve overall quality of life.
Conclusion: Based on the results of this systematic review, psilocybin-assisted psychotherapy may serve as an innovative and effective therapeutic option for managing anxiety and depression in cancer patients. However, further research is needed to better understand its effects, safety, potential benefits, and risks before it can be widely implemented in clinical practice. This study reinforces the potential of psilocybin as a complementary intervention for reducing depression and anxiety disorders in cancer patients.
References
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology. 2016 Dec 1;30(12):1181–97.
Agrawal M, Shnayder S, Honstein H, Emanuel EJ, Thambi PM. Long term efficacy of psilocybin in patients with cancer and major depressive disorder (MDD). Journal of Clinical Oncology. 2023;41(16_suppl):12021–12021.
Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015 Oct 15;78(8):572–81.
Nichols DE. Phychedelics. Pharmacol Rev. 2016;(April):264–355.
Reynolds CF. Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression - Quo Vadis? JAMA Psychiatry. 2021;78(5):476–8.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine. 2021;384(15):1402–11.
Tylš F, Páleníček T, Horáček J. Psilocybin - Summary of knowledge and new perspectives. Vol. 24, European Neuropsychopharmacology. 2014. p. 342–56.
Rucker JJ, Marwood L, Ajantaival RLJ, Bird C, Eriksson H, Harrison J, et al. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. Journal of Psychopharmacology. 2022 Jan 1;36(1):114–25.
Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry [Internet]. 2016;3(7):619–27. Available from: http://dx.doi.org/10.1016/S2215-0366(16)30065-7
Sudnitskaya J. Colorful drug pills on blue background, pharmaceutical concept.
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481–9.
McCrone P, Fisher H, Knight C, Harding R, Schlag AK, Nutt DJ, et al. Cost-effectiveness of psilocybin-assisted therapy for severe depression: Exploratory findings from a decision analytic model. Psychol Med. 2023;
Cochrane Handbook for Systematic Reviews of Interventions.
Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology. 2020 Feb 1;34(2):155–66.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology. 2016 Dec 1;30(12):1165–80.
Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, et al. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci. 2021 Apr 9;4(2):553–62.
Vargas AS, Luís Â, Barroso M, Gallardo E, Pereira L. Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials. Vol. 8, Biomedicines. MDPI AG; 2020.
Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol. 2020 Jan;34(2):167–80.
Bocchio M, McHugh SB, Bannerman DM, Sharp T, Capogna M. Serotonin, amygdala and fear: Assembling the puzzle. Vol. 10, Frontiers in Neural Circuits. Frontiers Media S.A.; 2016.
Cameron LP, Benson CJ, Defelice BC, Fiehn O, Olson DE. Chronic, Intermittent Microdoses of the Psychedelic N, N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem Neurosci. 2019 Jul 17;10(7):3261–70.
Barrett FS, Krimmel SR, Griffiths R, Seminowicz DA, Mathur BN. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage. 2020 Sep 1;218.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Agriefa Chrysantia Noormay El Kariim, Novia Tria Nurcahya, Novia Tria Nurcahya, Almira Clarissa Sungkono, Sherryn Sherryn, Yolanda Safitri
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
